Exchange: NYSE·Updated 04:45 PM EST

GKOS News

News
all
press releases
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL's strong product portfolio, surging Global High-Tech sales and digital expansion support growth prospects, even as persistent cost pressures weigh on margins.
Zacks
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
ECL's strong product portfolio, surging Global High-Tech sales and digital expansion support growth prospects, even as persistent cost pressures weigh on margins.
Zacks
More News
GE HealthCare advances manganese-based MRI agent to Phase 3 after positive trial data, potentially expanding its imaging portfolio and addressing gadolinium-related concerns.
Zacks
HIMS launches Peptides+ with five clinically guided therapies, expanding personalized wellness care through tailored treatments and ongoing medical support.
Zacks
Glaukos Corporation (NYSE:GKOS - Free Report) - Analysts at Zacks Research boosted their FY2026 EPS estimates for shares of Glaukos in a research report issued on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.42 per share for t...
MarketBeat
GEHC secures FDA clearance for AI-powered feeding tube detection software, expanding bedside X-ray capabilities for adult and pediatric patients.
Zacks
NPCE's RNS adoption, new indications and reimbursement gains offer growth potential, but weak sales execution and regulatory hurdles pose near-term risks.
Zacks
PHG launches cloud-based Skylight Device Manager to optimize ultrasound fleet management, boost equipment utilization and streamline healthcare operations.
Zacks
West Pharmaceutical's growth prospects are fueled by strong HVP demand, expanding biologics exposure and regulatory upgrades, despite near-term headwinds.
Zacks
Glaukos Corporation (NYSE:GKOS - Free Report) - Zacks Research raised their Q1 2028 earnings estimates for shares of Glaukos in a research note issued on Wednesday, November 18th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $0.27 per share for...
MarketBeat
Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 861 shares of the business's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $250.00, for a total value of $215,250.00. Following the sale, the chief operating officer owned...
MarketBeat

Advertisement|Remove ads.